We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
CorMedix Engages WSI PBG To Promote DefenCath For End-Stage Renal Disease Patients In VA And Federal Facilities
Express News | CorMedix Announces Collaboration for Defencath Promotion to the Va and Other Federal Facilities
CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities
CORMEDIX ANNOUNCES COLLABORATION FOR DEFENCATH PROMOTION TO THE VA AND OTHER FEDERAL FACILITIES
CorMedix Inc. (NASDAQ:CRMD) On The Verge Of Breaking Even
D. Boral Capital Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $15
Cormedix Analyst Ratings
D. Boral Capital Initiates CorMedix(CRMD.US) With Buy Rating, Announces Target Price $15
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix (CRMD) Receives a Buy From Truist Financial
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Cormedix Buy Rating: Strong Sales Performance and Expanding Customer Base Signal Positive Growth Prospects
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Sector Update: Health Care Stocks Mixed Premarket Tuesday
CorMedix Shares Advance After Reporting Preliminary Q4 Net Revenue
CorMedix | 8-K: CorMedix Inc. announces preliminary Fourth quarter 2024 results and provides business update
Express News | CorMedix Inc - Prelim, FY 2025 Operating Expense Guidance of $72-$78 Mln, Excluding Non-Cash & One-Time Items